Published in J Natl Cancer Inst on September 20, 2006
Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys (2015) 4.64
Heightened attention to medical privacy: challenges for unbiased sample recruitment and a possible solution. Am J Epidemiol (2010) 2.73
Tradeoffs between accuracy measures for electronic health care data algorithms. J Clin Epidemiol (2011) 2.06
Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst (2012) 1.70
Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care (2014) 1.24
The value of specialty oncology drugs. Health Serv Res (2009) 1.24
Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiol Drug Saf (2012) 1.20
Identifying primary and recurrent cancers using a SAS-based natural language processing algorithm. J Am Med Inform Assoc (2012) 1.01
Racial disparities in the development of breast cancer metastases among older women: a multilevel study. Cancer (2009) 1.00
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care (2008) 0.96
Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors. Ann Surg Oncol (2013) 0.95
Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer (2012) 0.91
Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. Med Care (2016) 0.90
Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. Ann Epidemiol (2014) 0.87
Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice? Springerplus (2014) 0.86
Development of a claims-based algorithm to identify colorectal cancer recurrence. Ann Epidemiol (2015) 0.84
Adjuvant Radiation and Outcomes After Breast Conserving Surgery in Publicly Insured Patients. J Geriatr Oncol (2012) 0.81
Use of a novel statistical technique to examine the delivery of breast cancer follow-up care by different types of oncology providers. J Eval Clin Pract (2016) 0.80
Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res (2012) 0.79
An algorithm to identify the development of lymphedema after breast cancer treatment. J Cancer Surviv (2014) 0.78
Preventive care receipt and office visit use among breast and colorectal cancer survivors relative to age- and gender-matched cancer-free controls. J Cancer Surviv (2014) 0.77
Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer. J Cancer Epidemiol (2012) 0.75
Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients. Thorac Cancer (2017) 0.75
Variation in the Types of Providers Participating in Breast Cancer Follow-Up Care: A SEER-Medicare Analysis. Ann Surg Oncol (2016) 0.75
Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. PLoS One (2015) 0.75
Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care (2015) 0.75
Challenges and opportunities in measuring cancer recurrence in the United States. J Natl Cancer Inst (2015) 0.75
An Electronic Health Record-based Algorithm to Ascertain the Date of Second Breast Cancer Events. Med Care (2015) 0.75
A Validation Study of Administrative Claims Data to Measure Ovarian Cancer Recurrence and Secondary Debulking Surgery. EGEMS (Wash DC) (2016) 0.75
An Electronic Health Record-based Algorithm to Ascertain the Date of Second Breast Cancer Events. Med Care (2017) 0.75
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
A primer and comparative review of major US mortality databases. Ann Epidemiol (2002) 6.59
Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol (2003) 4.77
Medicare's common denominator: the covered population. Health Care Financ Rev (1980) 4.37
Use of SEER-Medicare data for measuring cancer surgery. Med Care (2002) 4.27
Studying radiation therapy using SEER-Medicare-linked data. Med Care (2002) 4.13
Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer (1995) 3.78
An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res (2004) 2.75
Representation of older patients in cancer treatment trials. Cancer (1994) 2.06
Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care (2002) 1.87
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst (2005) 1.70
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Dynamic spread of happiness in a large social network: longitudinal analysis over 20 years in the Framingham Heart Study. BMJ (2008) 10.80
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Model of genetic variation in human social networks. Proc Natl Acad Sci U S A (2009) 8.73
Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol (2004) 7.45
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med (2009) 6.46
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol (2008) 5.61
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Cooperative behavior cascades in human social networks. Proc Natl Acad Sci U S A (2010) 5.00
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol (2006) 4.91
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
Dynamic social networks promote cooperation in experiments with humans. Proc Natl Acad Sci U S A (2011) 4.58
Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol (2003) 4.50
Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol (2007) 4.42
Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol (2009) 4.39
Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) (2006) 4.33
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ (2004) 4.13
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
The spread of alcohol consumption behavior in a large social network. Ann Intern Med (2010) 4.02
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst (2006) 4.01
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
A dynamic network approach for the study of human phenotypes. PLoS Comput Biol (2009) 3.62
Social networks and cooperation in hunter-gatherers. Nature (2012) 3.59
Physician factors associated with discussions about end-of-life care. Cancer (2010) 3.54
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol (2006) 3.50
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA (2005) 3.43
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) (2010) 3.24
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg (2003) 3.13
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Social networks and collateral health effects. BMJ (2004) 3.08
Geographic constraints on social network groups. PLoS One (2011) 3.08
Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet (2010) 3.07
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to". JAMA (2003) 2.98
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol (2010) 2.97
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol (2006) 2.87
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care (2005) 2.75
Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst (2002) 2.71
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol (2006) 2.69
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol (2008) 2.68
Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med (2008) 2.64
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Variation in patient-sharing networks of physicians across the United States. JAMA (2012) 2.59
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
Association of hospital spending intensity with mortality and readmission rates in Ontario hospitals. JAMA (2012) 2.47
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46
Self-perception of weight appropriateness in the United States. Am J Prev Med (2003) 2.41
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med (2009) 2.36
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
Alone in the crowd: the structure and spread of loneliness in a large social network. J Pers Soc Psychol (2009) 2.33
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol (2011) 2.31
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg (2006) 2.29
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer (2003) 2.26
Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol (2009) 2.26
The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr (2010) 2.25
The impact of cellular networks on disease comorbidity. Mol Syst Biol (2009) 2.23
Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Med Care (2013) 2.22
The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol (2005) 2.21
Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation. Radiology (2004) 2.21
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol (2007) 2.20